Fulcrum will leverage its experience and network of home diagnostic service providers, joining Kevin Winterfield as VP of Marketing and Communications, to accelerate brand awareness and sales.
LAKEWOOD RANCH, FL, December 1, 2022 (GLOBE NEWSWIRE) — via InvestorWire — brain science (OTCQB:BRSF), a Florida-based applied science and technology company, today announced a new distribution agreement with Fulcrum to drive sales, and the company has also hired Kevin Winterfield as vice president of marketing and communications. Accelerate Scientific’s strategic growth plans into the new year.
“Brain Scientific is poised for rapid expansion after completing key milestones including improved neurocapTMsBrain Scientific CEO Hassan Kotb said: “We are thrilled to have such experienced partners and colleagues joining our team at this important time in our history.”
Fulcrum, a leader in sales and marketing of B2B medical products, will further expand its sales and distribution network into what Brain Scientific sees as a key growth market to continue to maintain its leadership position in the rapidly emerging medical wearables market. helps. space.
“Brain Scientific’s vision for the world of wearables in the healthcare environment hits the mark. Starting with the revolutionary NeurocapTMs – Reduce EEG set-up time and provide a more user-friendly and comfortable environment for clinical staff and patients – They have shown that they know exactly where the field of applied science is heading. Reece Theriot, CEO of Fulcrum Sales and Marketing, said:
New Vice President of Marketing and Communications
Kevin Winterfield joins the Brain Scientific team as Vice President of Marketing and Communications. He brings extensive marketing and communications experience in the B2B technology space. Winterfield used IBM, Consumer Reports, TeamKCI and Bantam Tools to design and execute the campaign and develop the brand across identity creation, messaging, launch and sales. He also served as his EEG, calling out potential technologists early in his career and knowing firsthand that the wearables market is ripe for rapid innovation.
“I am thrilled to be joining this amazing team and am a strong believer in Brain Scientific’s vision of bringing amazing technology to people and reimagining how life works,” said Winterfield.
Winterfield is Daniel CloutierHe recently joined the Brain Scientific team as Chief Revenue Officer.
About Brain Scientific
Brain Scientific Co., Ltd. (brain science.com) is an applied science and technology company with multiple patents and FDA cleared products. Brain Scientific is committed to developing next-generation solutions that advance the future of medical and OEM devices. Brain Scientific has his two product lines covering neurology and precision movement. NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify management, reduce scan times and reduce costs.of piezo motion The product line consists of ultra-efficient miniature precision motors that power the next generation of OEM devices. For more information on Brain Scientific’s corporate strategy, products, or investor relations, please visit: brain science.com.
Statements contained in this press release that are not statements of historical fact may constitute forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding the following: (ii) projections of earnings (including gains/losses), earnings per share (including gains/losses), capital expenditures, dividends, capital structure or other financial items; (iii) future financial performance of the company; (iv) the successful integration of Piezo Motion and Brain Scientific; (v) assumptions underlying or relating to the statements set forth in (i), (ii), (iii), or (iv) above; Such forward-looking statements are not intended to predict or guarantee actual results, performance, events or circumstances, and are not intended to represent our current expectations, plans, objectives, beliefs, expectations, estimates and It is based on assumptions and is subject to numerous risks, uncertainties and other effects, many of which are beyond the Company’s control. Actual results, timing of particular events or circumstances may differ materially from those set forth in forward-looking statements as a result of these risks and uncertainties. Factors that could influence or contribute to the inaccuracy of forward-looking statements or that could cause actual results to differ materially from those anticipated or desired include the Company’s may not raise additional funds. The enormous amount of time and resources associated with product development and the associated inadequate cash flow and resulting illiquidity. The inability of the company to expand its business. Important government regulations for the medical device and healthcare industry. lack of product diversification; volatility in the company’s raw material prices; Failure to implement the company’s business plan or strategy. Some of these and other factors are identified and explained in more detail in the company’s filings with the SEC. We do not undertake to update these forward-looking statements.
IBN (Investor Brand Network)
Los Angeles, California